Roth Capital Analysts Give Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) a $14.00 Price Target

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) has been given a $14.00 price objective by research analysts at Roth Capital in a report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Roth Capital’s target price would indicate a potential upside of 54.36% from the company’s current price.

Several other brokerages also recently weighed in on AVDL. Zacks Investment Research downgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Langenberg & Company restated a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a research note on Thursday, September 7th. Ladenburg Thalmann Financial Services boosted their target price on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a research note on Thursday, September 7th. Finally, BidaskClub upgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) traded up $0.27 during trading hours on Wednesday, hitting $9.07. The stock had a trading volume of 268,891 shares, compared to its average volume of 235,350. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a twelve month low of $7.52 and a twelve month high of $12.30. The stock has a market cap of $352.74, a P/E ratio of 4.70 and a beta of 1.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last announced its earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.13. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 33.92% and a net margin of 44.47%. The firm had revenue of $39.68 million for the quarter, compared to the consensus estimate of $38.22 million. During the same period in the previous year, the business earned ($0.08) EPS. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. sell-side analysts forecast that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.35 EPS for the current fiscal year.

In other news, Director Craig R. Stapleton purchased 140,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were acquired at an average price of $8.67 per share, for a total transaction of $1,213,800.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were purchased at an average price of $8.86 per share, for a total transaction of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after purchasing an additional 10,532 shares during the last quarter. Nine Chapters Capital Management LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter valued at about $132,000. Sei Investments Co. grew its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after purchasing an additional 2,900 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 2nd quarter valued at about $181,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter valued at about $184,000. Institutional investors and hedge funds own 67.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Roth Capital Analysts Give Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) a $14.00 Price Target” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/03/roth-capital-analysts-give-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-a-14-00-price-target.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply